TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7500368
Drug: Emotionally Focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotionally Focused Therapy for Couples (EFT)
Study: 7179188
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative injection of BCG
Study: 11818701
Drug: Lisinopril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (up to 20 mg/day)
Study: 11818701
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (up to 90 mg/day)
Study: 29126212
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day for 9 weeks
Study: 26496098
Drug: 2-L Lactated
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L Lactated Ringer's (LR)
Study: 26496098
Drug: 2-L Normal
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L Normal Saline (NS)
Study: 26496098
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluid (noIVF)
Study: 24045789
Drug: Late-evening snack
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Late-evening snack (LES) containing 200 kcal (50 g CHO)
Study: 19050053
Drug: GIP +
Normalized name: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIP + 10 mg sulfonylurea (SU, glipizide)
Study: 16702497
Drug: Adapalene gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene gel, 0.1%
Study: 10776690
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 3 mg/kg per day
Study: 10776690
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 0.15 mg/kg per week
Study: 1300623
Drug: Dietary and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary and/or drug intervention
Study: 6542243
Drug: Cis-platinum at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-platinum at 8 mg/m2 with 4 l of i.v. hydration
Study: 6542243
Drug: Cis-platinum at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-platinum at 6 mg/m2 without i.v. hydration
Study: 23541975
Drug: Prolonged dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged dual antiplatelet therapy (DAPT)
Study: 21832181
Drug: Control stimuli
Normalized name: STIMULEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control stimuli not showing biological motion
Study: 19488984
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of levosulpiride tablet
Study: 17096435
Drug: Sip volumes
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sip volumes <=2.0 mL
Study: 15197790
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vascular-targeting agents with irradiation and other chemotherapeutic agents
Study: 9462904
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) with adequate lung inflation
Study: 8778745
Drug: Nifedipine treatment
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine treatment (10 mg t.i.d. for 5 days)
Study: 2515939
Drug: Levonorgestrel 0.03
Normalized name: levonorgestrel 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 0.03 mg daily
Study: 31509451
Drug: Delayed-treatment (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment (usual care)
Study: 26265231
Drug: Platelet function
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet function monitoring with drug adjustment in patients with poor response to antiplatelet therapy
Study: 26265231
Drug: Conventional strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional strategy without monitoring and drug adjustment
Study: 26265231
Drug: Intensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of antiplatelet treatment based on platelet function
Study: 10333376
Drug: CI‐988 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI‐988 (100 mg)
Study: 10333376
Drug: CI‐988 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI‐988 (25 mg)
Study: 1933997
Drug: Comparison drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison drug (Doxycycline or Amoxicillin-clavulanate)
Study: 6214989
Drug: Moxalactam (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (1,000 mg intramuscular injection)
Study: 6214989
Drug: Moxalactam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (1 g intravenous infusion)
Study: 6214989
Drug: Cefazolin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (0.5 g intravenous infusion)
Study: 10150324
Drug: Cefazolin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (0.5 g)
Study: 6330478
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg q.i.d. as i.v. bolus followed by 150 mg orally twice daily
Study: 6330478
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg q.i.d. intravenously and 1,000 mg daily orally in divided doses
Study: 29625605
Drug: Otorhinolaryngologic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otorhinolaryngologic surgery without involvement of the oral cavity
Study: 20431425
Drug: Fluarix (study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluarix (study vaccine)
Study: 20431425
Drug: Fluzone (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzone (control vaccine)
Study: 17507739
Drug: Carbohydrate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (1 g CHO/kg)
Study: 10331734
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily oral rifapentine doses of 150, 300, or 600 mg given on day 1 and again on days 4-10
Study: 10331734
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 600 mg dose given on days 1, 4, 7, and 10
Study: 1683337
Drug: Zotepine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (average daily dose of 168 +/- 15 mg)
Study: 1683337
Drug: Zotepine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (average daily dose of 241 +/- 70 mg)
Study: 1683337
Drug: Perazine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perazine (average daily dose of 348 +/- 09 mg)
Study: 7325348
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine during and after the operation
Study: 7325348
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg of morphine
Study: 12193097
Drug: Darusentan (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan (30, 100, 300 mg/day)
Study: 8130044
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia with isoflurane and nitrous oxide (group 1)
Study: 2782246
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate (ISDN) in Group C (without sustained ISDN therapy)
Study: 2782246
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate (ISDN) in Group N (with sustained ISDN therapy)
Study: 19884365
Drug: S/GSK1349572 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/GSK1349572 10 mg
Study: 19884365
Drug: S/GSK1349572 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/GSK1349572 50 mg
Study: 17077653
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (n = 27)
Study: 12809357
Drug: ImmunoGuard (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ImmunoGuard (4 mg Andrographolide per tablet, 48 mg daily, taken 3 times of 4 tablets daily for 1 month)
Study: 8637448
Drug: Voglibose (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.2 mg tablet before each test meal, 3 tablets per day)
Study: 2452175
Drug: New biochemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New biochemical method for assessing tissue damage via urinary excretion of hypoxanthine.
Study: 28326950
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% lidocaine medicated plaster
Study: 26265119
Drug: Transdermal granisetron
Normalized name: granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal granisetron (GTDS) - one GTDS patch for 7 days
Study: 26265119
Drug: Palonosetron -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron - iv 0.25 mg/day for 1 day
Study: 26265119
Drug: Transdermal granisetron
Normalized name: granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal granisetron (GTDS)
Study: 16735938
Drug: Estradiol 0.05
Normalized name: estradiol 0.05 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 0.05 mg/day
Study: 15592280
Drug: Raloxifene therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene therapy (60 mg/d every other day for 2 months followed by 60 mg/d)
Study: 11808544
Drug: Raloxifene therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene therapy
Study: 15592280
Drug: Slow-dose escalation
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-dose escalation of raloxifene therapy
Study: 1648142
Drug: CAV (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV (cyclophosphamide 800 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 IV on day 1)
Study: 1648142
Drug: PE (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE (cisplatin 80 mg/m2 IV on day 1, etoposide 100 mg/m2 IV on days 1, 3, and 5)
Study: 6499602
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral prednisolone
Study: 30119145
Drug: Epidural levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural levobupivacaine and morphine before incision (Group 1)
Study: 30119145
Drug: Epidural levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural levobupivacaine and morphine after incision (Group 2)
Study: 30119145
Drug: Epidural levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural levobupivacaine and morphine at the end of surgery (Group 3)
Study: 24183364
Drug: TA-ER (tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-ER (tramadol hydrochloride 75-mg/acetaminophen 650-mg)
Study: 21512394
Drug: Tailored irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored irinotecan and S‐1 therapy (arm A)
Study: 21512394
Drug: S‐1 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 monotherapy (arm B)
Study: 17714197
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of picture of chocolate with chocolate in the mouth in cravers
Study: 8961074
Drug: Moexipril 7.5
Normalized name: moexipril 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 7.5 mg once daily, increased to 15 mg once daily after 6 weeks if SDBP > 90 mm Hg
Study: 8961074
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg twice daily, increased to 50 mg twice daily after 6 weeks if SDBP > 90 mm Hg
Study: 2509064
Drug: Partial parenteral
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial parenteral plus enteral nutrition by tube feeding (PPN/EN)
Study: 26077768
Drug: Partially defatted
Normalized name: rice bran, defatted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially defatted Brazil nut flour (13 g/day providing 227.5 μg of selenium/day)
Study: 21663428
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (OROS MPH) 18, 36, and 54 mg QD after high-fat breakfast
Study: 21663428
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (OROS MPH) 18, 36, and 54 mg QD after normal breakfast
Study: 21663428
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (IR MPH) 5, 10, and 15 mg TID after normal breakfast
Study: 21663428
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (IR MPH) 5, 10, and 15 mg TID after fasting
Study: 19239703
Drug: Decremental PEEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decremental PEEP titration after ARM
Study: 16107868
Drug: Vacuum constriction
Normalized name: Alstonia constricta bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum constriction device (VCD) used daily for 9 months (Group 1, N=74)
Study: 16107868
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without any erectogenic treatment (Group 2, N=35)
Study: 15204157
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (eutectic mixture of local anesthetics)
Study: 8312148
Drug: Topical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agents for cutaneous infections in immunocompetent patients
Study: 8312148
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy for recurrent vulvovaginal candidiasis and oroesophageal candida infections
Study: 3552359
Drug: Sunitang (250,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitang (250, 500, and 1000 mg single oral doses)
Study: 3552359
Drug: Sunitang (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitang (additional treatment alongside original medications)
Study: 3552359
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (original medications only)
Study: 29230716
Drug: Visnadine spray
Normalized name: visnadine
DrugBank: Visnadine (DB13355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visnadine spray (ReFeel® spray), 2 puffs in the vulvar area, 10 minutes before sexual stimulation, for 30 days (n=30)
Study: 25452867
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg vitamin D3
Study: 25452867
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg vitamin D3
Study: 24785854
Drug: Continuous use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous use of oral contraceptive pills (OCPs)
Study: 24785854
Drug: Cyclic use
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic use of oral contraceptive pills (OCPs)
Study: 8835619
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) at a dose of 5 mg/kg body weight in addition to insulin therapy
Study: 8835619
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (insulin therapy only)
Study: 31233129
Drug: Drug disposal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug disposal bag provision
Study: 21292760
Drug: Placebo (as-needed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (as-needed β-agonist)
Study: 19681417
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (tidal volume 10 ml/kg with no positive end-expiratory pressure)
Study: 11576414
Drug: Cimetidine and
Normalized name: Cimetidine and sodium alginate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine and levamisole (combination treatment)
Study: 8034203
Drug: O‐(beta‐hydroxyethyl)‐rutosides (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O‐(beta‐hydroxyethyl)‐rutosides (HR) 250 mg 4 times daily (1 g/day), UK, n = 19 patients
Study: 8034203
Drug: O‐(beta‐hydroxyethyl)‐rutosides (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O‐(beta‐hydroxyethyl)‐rutosides (HR) 300 mg 3 times daily (900 mg/day), FRG and Belgium, n = 55
Study: 8034203
Drug: O‐(beta‐hydroxyethyl)‐rutosides (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O‐(beta‐hydroxyethyl)‐rutosides (HR) 300 mg 4 times daily (1,200 mg/day), The Netherlands, n = 30
Study: 2883906
Drug: Oxprenolol 20
Normalized name: oxprenolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 20 mg
Study: 786673
Drug: Oxprenolol 60
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol 60 mg
Study: 786673
Drug: Dihydralazine 30
Normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine 30 mg
Study: 786673
Drug: Hydrochlorothiazide 30
Normalized name: hydrochlorothiazide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 30 mg
Study: 30950450
Drug: Various adjuvant
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various adjuvant treatments including locoregional and systemic therapies as per trials mentioned (MAGIC, Intergroup 0116, ACTS‐GC, CLASSIC, ARTIST, CRITICS)
Study: 23211475
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone for 16 weeks
Study: 21255472
Drug: Glucose (intragastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (intragastric infusion)
Study: 21255472
Drug: Fructose (intragastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (intragastric infusion)
Study: 21255472
Drug: Artificial Sweeteners
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial Sweeteners (AS: aspartame, acesulfame K, sucralose) (intragastric infusion)
Study: 21255472
Drug: 2-deoxy-d-glucose (intragastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-deoxy-d-glucose (intragastric infusion)
Study: 15798546
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mg/kg) and succinylcholine (0.75 mg/kg)
Study: 15798546
Drug: Etomidate (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.15 mg/kg) and succinylcholine (0.75 mg/kg)
Study: 14514937
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mg once daily in the morning (09.00 hours)
Study: 14514937
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mg once daily in the evening (21.00 hours)
Study: 1631878
Drug: Bupivacaine hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine hydrochloride 0.5% solution, 10 ml/h
Study: 1631878
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% solution, 10 ml/h
Study: 31795359
Drug: Dose-dense weekly
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose-dense weekly paclitaxel (80 mg/m2) and low-dose triweekly cisplatin (20 mg/m2)
Study: 24614605
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative therapy (OMT)
Study: 16028386
Drug: Profenid administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profenid administered per rectum (100 mg)
Study: 16028386
Drug: Profenid administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profenid administered intravenously (100 mg)
Study: 12601511
Drug: Pelvicol implant
Normalized name: Delzicol
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pelvicol implant (n=74)
Study: 12601511
Drug: Pelvicol implant
Normalized name: Delzicol
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pelvicol implant
Study: 10684389
Drug: Positive patch
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive patch tests
Study: 3861138
Drug: Intracervical PGE2-gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2-gel (0.5 mg)
Study: 3861138
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal suppositories (2.0 mg)
Study: 25298575
Drug: Nebivolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (2.5 mg, 5 mg, 10 mg)
Study: 25298575
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (25 mg, 50 mg, 100 mg)
Study: 21134821
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy doublet fluoropyrimidine (5-FU or capecitabine) plus cisplatin (FP) every three weeks
Study: 12578781
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) 40 mg, administered orally, three times daily for 4 weeks
Study: 12578781
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules filled with 40 mg fructose)
Study: 10547209
Drug: Insulin added
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin added to glibenclamide therapy during phase I (4 months)
Study: 10547209
Drug: GAD-antibody status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-antibody status
Study: 1801688
Drug: GM-CSF after
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF after chemotherapy
Study: 1801688
Drug: GM-CSF as
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF as a priming agent 24 hours prior to chemotherapy
Study: 29166336
Drug: Valganciclovir prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir prophylaxis (2 × 450 mg/d for 100 days)